Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs

Ismat Lotia Farrukh,Nathalie Lachenal,Malik M. Adenov,Saman Ahmed,Yerkebulan Algozhin,Sylvine Coutisson,Epifanio Sanchez Garavito,Catherine Hewison,David Holtzman,Helena Huerga,Aleeza Janmohamed,Palwasha Y. Khan,Gamarly Leblanc Jacques,Nino Lomtadze,Nara Melikyan,Carole D. Mitnick, Gulnaz Mussabekova,Elna Osso, Sara Perea,Fauziah Asnely Putri, Mahmud Rashidov,Michael L. Rich, Yekaterina Sakhabutdinova,Kwonjune J. Seung,Assel Stambekova,Dante Vargas Vasquez,Molly F. Franke,Uzma Khan

CLINICAL INFECTIOUS DISEASES（2024）

引用 0|浏览25

暂无评分

摘要

Among 43 pregnant women receiving multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment with bedaquiline and/or delamanid, 98% had favorable treatment outcomes. Of 31 continued pregnancies, 81% had live births with no reported malformations, and 68% of neonates had normal birth weights. Effective MDR/RR-TB treatment during pregnancy can improve maternal outcomes without harming neonates.

查看译文

关键词

tuberculosis,drug resistance,pregnancy,outcome,treatment

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要